PDX1

Across TCGA pan-cancer cohorts, PDX1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PDX1 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PDX1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PDX1 expression acts as an unfavorable survival marker.

HNSC, STAD, and ACC are the cancer types where PDX1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.122	0.696	<.001	45	view →
STAD	OS	Median	All	0.184	0.730	.001	33	view →
ACC	DFS	Median	II,III,IV	0.242	0.724	.034	6	view →
LIHC	OS	Median	All	0.166	0.786	<.001	6	view →
SKCM	DFS	Median	II,III,IV	0.192	0.707	.046	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PDX1–HNSC (DFS)

Open the HNSC breakdown →